Pacira BioSciences Q4 revenue rises 5% yr/yr

Pacira Biosciences

26/02/2026 21:17

Overview

Non-opioid pain therapy firm's Q4 revenue rises 5% yr/yr

Adjusted net income for 2025 missed analyst expectations

Company repurchased 2 mln shares in Q4 for $50 mln

Outlook

Pacira projects 2026 EXPAREL net product sales of $600 to $620 mln

Company expects total revenue of $745 mln to $770 mln for 2026

Pacira anticipates non-GAAP gross margin of 77 to 79 percent in 2026

Result Drivers

EXPARAL SALES - Record-high sales driven by 7% volume growth, marking strongest Q4 performance in three years

EXPANDING REIMBURSEMENT - EXPAREL benefits from expanding reimbursement and growing commercial adoption

Company press release: ID:nGNX2vzVBn

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted Net Income
Miss
$122.30 mln
$139.80 mln (6 Analysts)
FY Net Income
$7 mln
FY Adjusted EBITDA
Miss
$186.50 mln
$203.99 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Pacira Biosciences Inc is $28.00, about 19.4% above its February 25 closing price of $23.46

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)